Story perspectives

New Drug Cobenfy Aims to Transform Psychosis Treatment

11/7/2025

47 9

Summary

Story summary

A Nature Mental Health study led by Michael Halassa at Tufts University tests Cobenfy, a xanomeline and trospium chloride combination, for psychosis affecting about 100,000 Americans annually.
The study analyzed data from 49 patients with schizophrenia, schizoaffective disorder, or bipolar disorder.
Cobenfy targets muscarinic receptors, differing from traditional antipsychotics that block dopamine D2 receptors.
The findings suggest precision psychiatry to tailor treatments to individual symptom profiles to improve recovery outcomes.

1 of 1

Story summary

A Nature Mental Health study led by Michael Halassa at Tufts University tests Cobenfy, a xanomeline and trospium chloride combination, for psychosis affecting about 100,000 Americans annually.
The study analyzed data from 49 patients with schizophrenia, schizoaffective disorder, or bipolar disorder.
Cobenfy targets muscarinic receptors, differing from traditional antipsychotics that block dopamine D2 receptors.
The findings suggest precision psychiatry to tailor treatments to individual symptom profiles to improve recovery outcomes.